Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed wants full recognition of ISO 13485

This article was originally published in The Silver Sheet

Executive Summary

Device trade association AdvaMed is urging FDA to move more quickly to fully recognize ISO 13485, the international quality system standard for medical device manufacturing. "We believe it would be good ... for FDA to recognize ISO 13485 because companies operate in a global environment," Janet Trunzo, AdvaMed's executive VP of technology and regulatory affairs, told "The Silver Sheet." "Because quality system management programs are such an integral part of medical device manufacturing, the safety and effectiveness of medical devices is not dependent on FDA and the frequency of FDA inspections," she said. Inspections are "a core function of FDA, but the quality management systems and compliance to ISO 13485 ... also is a very important part of a company's programs." ISO 13485's requirements for firms are not identical to the Quality System Regulation, although the two regimes are "95 percent alike," Trunzo noted. The agency recently released a draft guidance that would allow the results of ISO inspections to be a factor in FDA's decision whether to conduct its own inspections ("The Silver Sheet" June 2010)

You may also be interested in...



Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel